EGFR and glioblastoma: EGFRvIII activates the NF-κB (nuclear factor κB) pathway and increases the aggressiveness of GBM, and cancer cells expressing EGFRvIII are more sensitive to EGFR tyrosine kinase inhibitors (TKIs) (34, 35).